EcoDrugPlus

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSOMYG00000011723
Gene Symbol: GABBR2
1 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSOMYG00000016401
Gene Symbol: GABBR2
1 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSOMYG00000005915
Gene Symbol: GABRA1
1 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSOMYG00000055306
Gene Symbol: GABRA1
1 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSOMYG00000004656
Gene Symbol: GABRA4
1 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSOMYG00000044782
Gene Symbol: GABRA4
1 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSOMYG00000002468
Gene Symbol: GABRA5
1 Cross references
205 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSOMYG00000005834
Gene Symbol: GABRA6
1 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSOMYG00000064866
Gene Symbol: GABRA6
1 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6a

Ensembl ID : ENSOMYG00000024007
Gene Symbol: GABRA6A
1 Cross references
63 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6a

Ensembl ID : ENSOMYG00000058409
Gene Symbol: GABRA6A
1 Cross references
63 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSOMYG00000034072
Gene Symbol: GABRB1
1 Cross references
96 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).